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MICROWAVE-ASSISTED SYNTHESIS AND ANTIBACTERIAL ACTIVITY 
OF SOME PYRAZOL-1-YLQUINOXALIN-2(1H)-ONE DERIVATIVES 
 
 
3-Hydrazinoquinoxalin-2(1H)-one was prepared from quinoxaline-2,3-dione and 
subsequently used for the synthesis of some potentially biologically active 3-(pyrazol-1-
ylquinoxalin-2(1H)-one derivatives. While 3-(3,5-dimethylpyrazol-1-yl)quinoxalin-
2(1H)-one showed a comparative effect with streptomycin, 3-(5-oxo-3-phenyl-4,5-di- 
hydropyrazol-1-yl)quinoxalin-2(1H)-one was found to be the most active at MIC value 
of 7.8 µg/ml. 
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Over the years, it has been established that quinoxalines are, in general, 
relatively easy to prepare [1–3] and many derivatives have been synthesized 
with the aim of obtaining biologically active materials [4, 5]. Some quinoxaline 
and quinoxalinone derivatives have been reported to show antimicrobial [6, 7], 
anti-inflammatory [8], antifungal [9], anticancer [10], antiviral [11], 
antimalarial [12], anticonvulsant [13], antidepressant [14], antitubercular [15], 
antibacterial [16], and antithrombotic [17] activities. 
Thermal and chemically stable polyquinoxalines (PQs) find potential 
applications as films, coating adhesives [18], ultrafiltering materials, and 
composite matrices that demand stability in harsh environment [19]. In a 
similar manner, the synthesis of novel pyrazole derivatives [20] and evaluation 
of their chemical behaviours have gained more importance in the recent 
decades for biological [21–23], medicinal [24], and agricultural [25] purposes. 
Although numerous methods are available for construction of pyrazoles [26, 
27], only little attention has been given to the pyrazolysis of quinoxalinone 
derivatives [28]. For instance, 1,3-dipolar cycloadditions of azomethine imines, 
available by acid catalyzed treatment of 3-pyrazolidinone with acetone and 
butyraldehyde, respectively, were studied [29]. Photoluminescence and 
electroluminescence of some new 1H-pyrazolo[3,4-b]quinoxaline derivatives 
have been investigated [30] while the biological properties of such moieties 
have been understudied [31]. From this point of view, it is of great interest to 
synthesize some pyrazolylquinoxalinone derivatives with the aim of 
investigating their antibacterial properties. 
3-Hydrazinoquinoxalin-2(1H)-one (2) was prepared from hydrazinolysis of 
1,2,3,4-tetrahydroquinoxaline-2,3-dione (1), which existed as a keto-enol 
tautomer (Scheme 1). The starting material 1 was prepared by the modified 
Obafemi and Pfleiderer procedure [32].  To a heated (100oC) solution of oxalic  
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acid dihydrate in water, acidified o-phenylenediamine cautiously with vigorous 
stirring at 100oC for 20 min was added. The resulting mixture was cooled and 
then filtered off. The crude solid obtained was purified by crystallization from 
water to afford colorless needles of compound 1. 3-Hydrazinoquinoxalin-
2(1H)-one 2 underwent condensation reaction with various β-diketones to 
afford (3,5-disubstituted pyrazol-1-yl)quinoxalin-2(1H)-one derivatives 3–7 in 
excellent yields (Scheme 1). For instance, the reaction of compound 2 with 2-
thenoyltrifluoroacetone gave 97% of 2-trifluoromethyl-substituted pyrazole 7 as 
a single product. This is because the carbonyl next to CF3 is more reactive than 
the carbonyl next to thiophene due to a high electron withdrawing ability of 
trifluoromethyl side chain. Therefore, the nucleophilic attack by NH2 of 
hydrazine was initiated first on the carbonyl next to CF3. 
Furthermore, the condensation of compound 2 with α-keto esters followed 
by thermal cyclization of the reaction intermediate in the presence of ethanol 
solvent gave the target structure of (3-alkyl(aryl)-5-oxo-4,5-dihydropyrazol-1-
yl)quinoxalin-2(1H)-one derivatives 8, 9. The carbonyl of ketone is being 
attacked first since it is more reactive than the carbonyl of ester. Finally, upon 
the treatment of compound 2 with ethyl cyanoacetate the main product obtained 
was 3-(3-amino-5-oxo-4,5-dihydropyrazol-1-yl)quinoxalin-2(1H)-one (10) in 
moderate yield (Scheme). Melting points of all compounds were on the high 
side (177 to > 360°C) as a result of the presence of amide bonds and probable 
existence of intramolecular hydrogen bonding.  
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The IR spectra of compounds 1–10 showed absorption bands due to the 
stretching vibrations of N–H, C=O, C=C, and C=N at 3470–3132, 1705–1648, 
1620–1600, and 1580–1509 cm–1, respectively. The IR spectrum of compound 9 
showed a broad band at 3302 cm–1 due to the stretching vibration of N–H, while 
its two carbonyl stretching vibration appeared at 1703 and 1648 cm–1, 
respectively. The IR absorption band at 1600 cm–1 depicted the presence of 
aromatic C=C, while C=N band was observed at 1509 cm–1. UV-visible 
spectrum of compound 9 gave rise to wavelength (λmax) at 208 and 352 nm, 
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while a shoulder was observed at 244 nm. The wavelength at 208 nm is a result 
of π→π* transition of the phenyl ring, while 352 nm is a result of contribution 
from the pyrazolyl ring. The electronic transition in UV-visible spectra gave 
rise to wavelength (λmax) ranging from 205 to 372 nm. Bathochromic shift was 
observed in compounds 3–10 compared with the precursor 2. This might be as a 
result of extensive conjugation of π-electrons  from  the pyrazolyl  ring and σ-
donating character of alkyl groups experienced in the former. The chemical 
shifts and multiplicity patterns in NMR spectra correlated well with the 
proposed structures. For instance, the 1H NMR of compound 9 showed a broad 
singlet corresponding to resonance of N–H of amide at δ 8.00 ppm and it was 
exchangeable with D2O. The multiplet at δ 7.52–7.94 ppm confirmed the 
presence of five aromatic protons of phenyl attached to azomethine carbon in 
position 3 of the pyrazolyl ring, while the multiplet at δ 7.08–8.27 ppm 
indicated the presence of four aromatic protons of benzo-fused part of the 
quinoxaline nucleus of compound 9. The position of the pyrazole double bond 
was confirmed to be between nitrogen and carbon as a result of a singlet at 
δ 2.20 ppm, which was due to presence of two methylene protons (pyrazole 
CH2). The 13C NMR of compound 9 revealed seventeen carbon atoms with two 
C=O having highest signals at 165.0 and 158.0 ppm, while fourteen sp2-hybri- 
dized carbon atoms appeared at 157.6–115.2 ppm. The one CH2 carbon atom 
appeared to have the least signal at δ 35.1 ppm.  
In addition, the mass spectrum of compound 9 showed a molecular ion peak 
at m/z 304 [M+] with relative intensity of 54.3%, its mass spectrum was also 
characterized by the occurrence of a base peak at m/z 227 [M+–77(Ph.)], which 
was the  result of the phenyl radical loss. Out of the three pyrazolone 
derivatives 8–10 only compound 9 had the highest steric effect due to the 
presence of a bulky substituent, which is a weakly activating group in C-3 
position of pyrazolone ring, while compounds 8 and 10 had a low to moderate 
steric interaction due to the presence of smaller groups (CH3 and NH2).  
Ten compounds 1–10 were screened in vitro for possible antibacterial 
activities using agar well diffusion method [33], while minimum inhibitory 
concentration test was carried out using Russell and Furr method [34]. The 
sensitivity testing (inhibition zones, mm) of the compounds and streptomycin (a 
reference clinical antibiotic) in DMSO (solvent) at 1000 µg/ml against nine 
gram-positive and five gram-negative bacterial strains is reported in Table 1. 
The results indicated that starting materials 1–2 and the reaction products 3–10 
as well  as  streptomycin  showed a broad spectrum against the bacterial strains.  
Compound 3 has been synthesized before by conventional heating method 
[35], however, microwave assisted approach has not been used for compound 3 
to the best of our knowledge, also its antibacterial activity has not been 
investigated. Escherichia coli and Klebsiella pneumonia developed a resistance 
against streptomycin, whereas all the compounds were active as to these two 
bacteria. Most of the compounds were not active on Corynebacterium pyogene, 
Bacillus polymyxa, and Pseudomonas fluorescence, whereas streptomycin was 
active on those bacteria mentioned.  
Considering the pyrazolyl derivatives 3–7, compound 3 with a lower steric 
hindrance due to the presence of a smaller side chain (CH3) was observed to 
have a larger  inhibition zone and a  lower MIC value of 7.8 µg/ml as compared  
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Table 1: Antibacterial screening (sensitivity testing) on bacteria with inhibition zones  
 
Bacteria  
Antibacterial activity* 
1 2 3 4 5 6 7 8 9 10 Str.** 
Corynebacterium pyogene (LIO) + R R R R R R R R R +++ 
Bacillus polymyxa (LIO) ++ R R R R R R ++ ++ R ++ 
Bacillus stearothermophilus 
(NCIB 8222) 
 
+++ ++ ++ ++ ++ ++ ++ ++ ++ +++ ++ 
Bacillus subtilis (NCIB 3610) 
 
+++ +++ ++ + + ++ + ++ +++ +++ +++ 
Bacillus anthracis (LIO) ++ +++ ++ ++ ++ + + +++ +++ + ++ 
Bacillus cereus (NCIB 6349) +++ ++ ++ ++ ++ + ++ +++ +++ +++ +++ 
Streptococcus faecalis 
(NCIB775) 
+++ ++ +++ ++ + + ++ + +++ R +++ 
Staphylococcus aureus 
(NCIB 8588)  
+++ R R R R R + + R ++ +++ 
Clostridium sporogenes (LIO) +++ + + R R R R + + R +++ 
Escherichia coli (NCIB 86) +++ +++ +++ +++ +++ +++ ++ +++ ++ +++ R 
Pseudomonas fluorescence 
(NCIB 3756) 
R R R R R R R ++ 
 
R R +++ 
Klebsiella pneumonia 
(NCIB 418)  
++ + ++ 
 
++ + + +++ ++ + + R 
Shigella dysenteriae (LIO) +++ +++ ++ + ++ ++ ++ ++ ++ R +++ 
Pseudomonas aeruginosa 
(NCIB 950) 
+ ++ ++ ++ + ++ R ++ ++ R  
____________ 
* R – resistance,  + –  less active (0.5–1.2 mm),  ++ – moderately active (1.3–1.9 
mm),  +++ –  highly active (2.0–3.1 mm). 
    ** Str. – streptomycin. 
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Table 2: Minimum inhibitory concentration (MIC) test of the compounds on some selected 
bacteria  
 
Bacteria 
MIC, µg/ml 
1 2 3 4 5 6 7 8 9 10 Str. 
B. stearothermophilus 
(NCIB 8222) 
7.8 15.6 15.6 31.3 31.3 15.6 15.6 62.5 15.6 31.3 31.3 
Bacillus subtilis 
(NCIB 3610) 
62.5 15.6 15.6 250.0 250.0 31.3 62.5 62.5 7.8 7.8 7.8 
Bacillus anthracis (LIO) 31.3 500.0 31.3 31.3 15.6 250.0 31.3 7.8 7.8 250.0 31.3 
Streptococcus faecalis 
(NCIB 775) 
7.8 250.0 7.8 15.6 250.0 250.0 7.8 31.5 7.8 R 15.6 
Bacillus cereus  
(NCIB 6349) 
7.8 15.6 15.6 15.6 31.3 62.5 15.6 7.8 7.8 62.5 31.3 
Escherichia coli  
(NCIB 86) 
62.5 7.8 7.8 15.6 15.6 15.6 62.5 7.8 15.6 7.8 R 
Pseudomonas fluorescence 
(NCIB3756) 
R R R R R R R 250.0 R R 7.8 
Klebsiella pneumonia 
(NCIB 418)  
7.8 250. 7.8 31.3 62.5 31.3 15.6 62.5 7.8 250.0 R 
Shigella dysenteriae (LIO) 
 
15.6 31.3 250.0 62.5 62.5 31.3 31.3 31.3 62.5 R 62.5 
Pseudomonas aeruginosa 
 (NCIB 950) 
7.8 15.6 15.6 15.6 250.0 31.3 R 250.0 31.3 R R 
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to compounds 4–7. So, it was discovered that the occurrence of steric hindrance 
created by the substituents on the pyrazolyl ring might have a probable effect 
on the biological activity of such moieties. On the other hand, considering the 
pyrazolone ring of compounds 8–10, only compound 9 experienced an 
extensive conjugation due to the presence of phenyl group in C-3 position. 
Thus, compound 9 had a better activity as compared to compounds 8 and 10. 
In fact, compound 9 was the most active on the Bacillus species at MIC value 
of 7.8 µg/ml except for Bacillus anthracis, where the inhibition was at a 
concentration of 15.6 µg/ml.  
Based on the size of inhibition zones and the resistance degree observed, the 
minimum inhibitory concentration (MIC) test was selectively carried out on 
five gram-positive and five gram-negative bacterial isolates (Table 2). The MIC 
of compounds 1, 2 varied between 7.8 and 500 µg/ml, it was between 7.8 and 
250 µg/ml for compounds 3, 8, 10 and between 15.6 and 250.0 µg/ml for 
compounds 4–6. Finally, compounds 7, 9 inhibited the bacterial growth at MIC 
range between 7.8 and 62.5 µg/ml. Overall result indicated that out of all the 
compounds prepared, compound 9 had the highest activity at 7.8 µg/ml, while 
compounds 1, 3 appeared to compete favourably with streptomycin at 15.6 and 
7.8 µg/ml on both the gram-positive and gram-negative bacteria. In particular, 
the π−π interaction experienced in the phenyl side chain in compound 9 might 
also be a contributing factor to the reasonably high activity observed in 
compound 9.  
In summary, we constructed a workable pathway and synthesized a series of 
(3,5-alkyl(aryl)pyrazol-1-yl)quinoxalin-2(1H)-ones 3–7, 3-alkyl(aryl)-5-oxo-
4,5-dihydropyrazol-1-yl)quinoxalin-2(1H)-one 8, 9, and 3-(3-amino-5-oxo-4,5-
dihydropyrazol-1-yl)quinoxalin-2(1H)-one 10, which were structurally confirmed 
by IR, UV, 1H NMR, 13C NMR, and MS spectral analyses and evaluated for 
antibacterial activity by the growth inhibition of some gram-positive and gram-
negative bacterial strains. By visualizing the antimicrobial data it could be 
observed that some of the compounds possess a significant activity. In fact, the 
results show that the compounds exhibited a high potency as antibacterial 
agents. The most active compound was 3-(5-oxo-3-phenyl-4,5-dihydropyrazol-
1-yl)quinoxalin-2(1H)-one (9) with an MIC value of 7.8 µg/ml. Thus, the 
pyrazol-1-ylquinoxalin-2(1H)-one derivatives synthesized as well as the starting 
material may seem promising for further activity optimization studies. 
 
EXPERIMENTAL 
 
Melting points were determined with an open capillary tube on a Gallenkamp 
(variable heater) melting point apparatus and were uncorrected. IR spectra were 
recorded as KBr pellets on a Buck Spectrometer, while UV-visible spectra were 
recorded on a Unicam Spectrophotometer using a methanol solvent. 1H and 13C NMR 
were run on a Bruker AC-50 and JEOL-JNM-GX 400-MHz spectrometer in MeOH-d4 
(compounds 2−9) and DMSO-d6 (compound 10) (δ in ppm relative to Me4Si). Mass 
spectra were registered on Finnigan MAT 312 machine. All compounds were routinely 
checked by TLC on silica gel G plates using CHCl3 : MeOH (9:1, v/v) solvent system 
and the developed plates were visualized by UV light. The elemental analyses (C, H, N) 
of compounds were performed using a Carlo Erba-1108 elemental analyzer. The 
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solvents used were of the reagent grade and, when necessary, were purified and dried by 
standard methods. The microwave-assisted syntheses were carried out in domestic oven, 
Midea PJ21B-A 400W.  
1,2,3,4-Tetrahydroquinoxaline-2,3-dione (1). To a heated to 100°C and stirred 
solution of oxalic acid dihydrate (30.0 g, 238.0 mmol) in water (200 ml) concentrated 
HCl (45 ml) was added, followed by o-phenylenediamine (22.0 g, 204.0 mmol) with 
continuous stirring at 100°C for 20 min. The resulting mixture was cooled by addition of 
crushed ice (100 g) to give silvery white needles, which were collected by filtration, 
washed with water, and oven dried to afford compound 1 (32.3 g, 98.0%) as colourless 
needles; mp > 340°C (EtOH) (Lit. mp > 340°C [32, 36]). Other physical and 
spectroscopic data were identical to those of the authentic sample. 
3-Hydrazinoquinoxalin-2(1H)-one (2). To a mixture of compound 1 (20.1 g, 
124.0 mmol) and hydrazine hydrate (100.0 ml, 2.2 mol) water (50 ml) was added and 
the resulting mixture was refluxed for 3 h. The mixture was allowed to cool and the 
formed precipitate was filtered off, recrystallized from ethanol to give compound 2 
(19.8 g, 90%) as a yellow solid; mp > 360°C.  IR spectrum, νmax, cm–1: 3412 (N−H), 
3280 (N−H), 3175 (N−H), 1679 (C=O), 1620 (C=C). UV spectrum, λmax (log εmax): 216 
(4.34), 247 (3.75 s), 327 (3.61 s). 1H NMR spectrum, δ, ppm: 5.81 (2H, br. s, NH2, D2O 
exchangeable); 7.09–8.26 (4H, m, H Ar); 8.14 (1H, s, NH, D2O exchangeable); 12.55 (1H, 
s, NH, D2O exchangeable). 13C NMR spectrum, δ, ppm: 158.0 (C=O), 157.6, 142.7, 
131.7, 129.1, 125.9, 123.5, 115.2. Mass spectrum, m/z (Irel, %): 176 [M+] (55.5), 161 
(92.3), 146 (85.5), 118 (100), 106 (80.1), 78 (40.5). Found, %: C 54.52; H 4.57; 
N 31.83. C8H8N4O. Calculated, %: C 54.55; H 4.55; N 31.82. 
3,5-Disubstituted pyrazolyl derivatives 3–7 (General procedure). To a solution of 
compound 2 (1.0 g, 5.7 mmol) in β-diketone (5.7 mmol) ethanol (10 ml) was added and 
irradiated in a domestic microwave oven (MW) at an emitted power of 400 W for the 
appropriate period. The clear solution formed was left to stand at room temperature 
to crystallize. The solid crude product was recrystallized from the appropriate solvent 
to afford 3,5-disubstituted (pyrazol-1-yl)quinoxalin-2(1H)-one.  
3-(3,5-Dimethylpyrazol-1-yl)quinoxalin-2(1H)-one (3). Reagents: compound 2 
(1.0 g, 5.7 mmol), acetyl acetone (1.0 ml, 5.7 mmol), ethanol (10 ml). Conditions: 
3 min, 400 W, MWI. Purification: recrystallization. Yield (1.3 g, 99.0%) as a brown 
solid; mp 177–179°C (EtOH). IR spectrum, νmax, cm–1: 3436 (N–H), 1679 (C=O), 1618 
(C=C). UV spectrum, λmax (log εmax): 208 (4.28), 239 (3.97 s), 325 (3.66 s), 352 (3.73). 
1H NMR spectrum, δ, ppm: 2.30 (3H, s, CH3); 2.48 (3H, s, CH3); 6.18 (1H, s, –CH=); 
7.09–8.27 (4H, m, H Ar); 8.00 (1H, s, NH, D2O exchangeable). 13C NMR spectrum, 
δ,  ppm: 157.6 (C=O), 152.3, 149.4, 143.2, 142.7, 131.7, 129.1, 125.9, 123.5, 115.2, 
110.2, 13.5 (CH3), 13.2 (CH3). Mass spectrum, m/z (Irel, %): 240 [M+] (100), 226 (68.3), 
212 (70.5), 146 (88.3), 106 (45.1), 78 (55.0). Found, %: C 65.02; H 5.01; N 23.36. 
C13H12N4O. Calculated, %: C 65.00; H 5.00; N 23.33.  
3-(5-Ethyl-3-methylpyrazol-1-yl)quinoxalin-2(1H)-one (4). Reagents: Compound 2 
(1.0 g, 5.7 mmol), hexane-2,4-dione (0.7 ml, 5.7 mmol), ethanol (10 ml). Conditions: 
5 min, 400 W, MWI. Purification: recrystallization. Yield 1.35 g (93.1%) as a colorless 
solid; mp 183–185°C (EtOH). IR spectrum, νmax, cm–1: 3430 (N–H), 1675 (C=O), 1620 
(C=C). UV spectrum, λmax (log εmax): 210 (4.12), 240 (3.95 s), 330 (3.85 s), 350 (3.51). 
1H NMR spectrum, δ,  ppm (J, Hz): 1.25 (3H, t, J = 7.2, CH3); 2.30 (3H, s, CH3); 3.07 
(2H, q, J = 7.2, CH2); 6.20 (1H, s, –CH=); 7.08–8.27 (4H, m, H Ar); 8.00 (1H, s, NH, 
D2O exchangeable). 13C NMR spectrum, δ, ppm: 157.6 (C=O), 152.3, 149.4, 144.5, 
142.7, 131.7, 129.1, 125.9, 123.5, 115.2, 104.9, 20.8 (CH2), 13.2 (CH3), 12.7 (CH3). Mass 
spectrum, m/z (Irel, %): 254 [M+] (89.1), 224 (66.3), 110 (100), 66 (57.5). Found, %: 
C 66.09; H 5.48; N 22.00. C14H14N4O. Calculated, %: C 66.14; H 5.51; N 22.05. 
3-(3-Methyl-5-propylpyrazol-1-yl)quinoxalin-2(1H)-one (5). Reagents: Compound 2 
(1.0 g, 5.7 mmol), heptane-2,4-dione (0.8 ml, 5.7 mmol), ethanol (10 ml). Conditions: 
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5 min, 400 W, MWI. Purification: recrystallization. Yield 1.38 g (90.2%) as a colourless 
solid; mp 204–205°C (EtOH). IR spectrum, νmax, cm–1: 3433 (N–H), 1685 (C=O), 1615 
(C=C), 1579 (C=N). UV spectrum, λmax (log εmax): 208 (4.05), 244 (3.88), 338 (3.63 s), 
370 (4.13). 1H NMR spectrum, δ, ppm (J, Hz): 0.90 (3H, t, J = 7.3, CH3); 1.65 (2H, 
sextet, J = 7.3, CH2); 2.30 (3H, s, CH3); 2.44 (2H, t, J = 7.3, CH2); 6.19 (1H, s, –CH=); 
7.09–8.27 (4H, m, H Ar); 8.00 (1H, s, NH, D2O exchangeable). 13C NMR spectrum, 
δ, ppm: 157.6 (C=O), 152.3, 149.4, 144.5, 142.7, 131.7, 129.1, 125.9, 123.5, 115.3, 
104.9, 31.1, 22.6, 13.7 (CH3), 13.2 (CH3). Mass spectrum, m/z (Irel, %): 268 [M+] (70.1), 
240 (65.2), 146 (85.3), 124 (52.1), 118 (100), 96 (92.3). Found, %: C 67.18; H 5.99; 
N 20.87. C15H16N4O. Calculated, %: C 67.16; H 5.97; N 20.90.  
3-(3,5-Diethylpyrazol-1-yl)quinoxalin-2(1H)-one (6). Reagents: Compound 2 (1.0 g, 
5.7 mmol), heptane-3,5-dione (0.8 ml, 5.7 mmol), ethanol (10 ml). Conditions: 5 min, 
400 W, MWI. Purification: recrystallization. Yield 1.41 g (92.2%) as a colorless solid: 
mp 192–193°C (EtOH/DMF). IR spectrum, νmax, cm–1: 3430 (N–H), 1690 (C=O), 1605 
(C=C). UV spectrum, λmax (log εmax): 209 (4.05), 245 (3.91), 372 (3.61). 1H NMR 
spectrum, δ, ppm (J, Hz): 1.25 (6H, t, J = 7.2, 2CH3); 3.07 (4H, q, J = 7.2, 2CH2); 6.22 
(1H, s, –CH=); 7.10–8.28 (4H, m, H Ar); 8.00 (1H, s, NH, D2O exchangeable). 
13C NMR spectrum, δ, ppm: 157.6 (C=O), 149.4, 146.8, 144.5, 142.7, 131.7, 129.1, 
125.9, 123.5, 115.2, 104.9, 20.8 (CH2), 19.5 (CH2), 13.2 (CH3), 12.7 (CH3). Mass spectrum, 
m/z (Irel, %): 268 [M+] (72.5), 240 (57.4), 212 (68.2), 146 (80.8). Found, %: C 67.13; 
H 5.92; N 20.92. C15H16N4O. Calculated, %: C 67.16; H 5.97; N 20.90.  
3-[5-Thien-2-yl-3-(trifluoromethyl)pyrazol-1-yl]quinoxalin-2(1H)-one (7). 
Reagents: Compound 2 (1.0 g, 5.7 mmol), 2-thenoyltrifluoroacetone (1.3 g, 5.7 mmol), 
30 ml of DMF–ethanol, 1:5. Conditions: 2 min, 400 W, MWI. Purification: 
recrystallization. Yield 2.0 g (97.0%) as an orange solid; mp 328–330oC (EtOH). 
IR spectrum, νmax, cm–1: 3241 (N–H), 1675 (C=O), 1620 (C=C), 1575 (C=N). UV spectrum,  
λmax (log εmax): 205 (3.38), 225 (3.00), 237 (2.51), 273 (3.10), 298 (3.70). 1H NMR 
spectrum, δ, ppm: 6.02 (1H, s, pyrazol –CH=); 7.69–7.17 (3H, m, H Th); 7.09–8.27 
(4H, m, H Ar); 8.00 (1H, s, NH, D2O exchangeable). 13C NMR spectrum, δ, ppm: 157.6 
(C=O), 149.4, 142.7, 139.9, 136.4, 131.7, 131.2, 129.1, 128.6, 128.0, 127.6, 125.9, 
123.5, 121.4, 115.2, 105.9. Mass spectrum, m/z (Irel, %): 362 [M+] (68.3), 294 (100), 
280 (31.5), 212 (70.4), 146 (85.1). Found, %: C 53.06; H 2.50; N 15.49. C16H9F3N4OS. 
Calculated, %: C 53.04; H 2.49; N 15.47.  
3-(5-Oxo-3-R-4,5-dihydropyrazol-1-yl)quinoxalin-2(1H)-ones 8, 9 (General procedure). 
To anhydrous compound 2 (1.0 g, 5.7 mmol) a homogenous mixture of β-keto ester 
(28.5 mmol) and ethanol (20 ml) was added dropwise at room temperature. The mixture 
was irradiated in a microwave oven at 15-s interval for the appropriate period to give 
a clear solution, which was left to stand at room temperature. The solid crude product 
was recrystallized from the appropriate solvent to afford compounds 8, 9.  
3-(3-Methyl-5-oxo-4,5-dihydropyrazol-1-yl)quinoxalin-2(1H)-one (8). Reagents: 
Compound 2 (1.0 g, 5.7 mmol), ethyl acetoacetate (3.6 ml, 28.5 mmol), ethanol (20 ml). 
Conditions: 3 min, 400 W, MWI. Purification: recrystallization. Yield 1.3 g (94.2%) as 
a yellow solid; mp 316–318oC (EtOH). IR spectrum, νmax, cm–1: 3448 (N–H), 1705 
(C=O), 1667 (C=O), 1610 (C=C). UV spectrum,  λmax (log εmax): 220 (3.13), 305 (5.10), 
320 (5.43 s). 1H NMR spectrum, δ, ppm: 1.94 (3H, s, CH3); 2.20 (2H, s, CH2 pyrazol); 
7.09–8.29 (4H, m, H Ar); 8.00 (1H, s, NH, D2O exchangeable). 13C NMR spectrum, 
δ, ppm: 165.0 (C=O), 159.5 (C=O), 158.2, 157.3, 142.4, 131.8, 129.0, 125.8, 123.6, 
115.1, 43.2, 16.4 (CH3). Mass spectrum, m/z (Irel, %): 242 [M+] (54.3), 228 (83.4), 214 
(100), 200 (75.4), 146 (86.1), 106 (24.5). Found, %: C 59.52; H 4.14; N 23.16. 
C12H10N4O2. Calculated, %: C 59.50; H 4.13; N 23.14.  
3-(5-Oxo-3-phenyl-4,5-dihydropyrazol-1-yl)quinoxalin-2(1H)-one (9). Reagents: 
Compound 2 (1.0 g, 5.7 mmol), ethyl benzoylacetate (4.9 ml, 28.3 mmol), ethanol (20 ml). 
Conditions: 2 min, 400 W, MWI. Purification: recrystallization. Yield 1.7 g (99.0%) as  
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a yellow solid; mp 287–288oC (EtOH). IR spectrum, νmax, cm–1: 3302 (NH), 1703 
(C=O), 1648 (C=O), 1600 (C=C), 1509 (C=N). UV spectrum, λmax (log εmax): 208 
(4.29), 244 (4.09 s), 352 (3.76). 1H NMR spectrum, δ, ppm: 2.20 (2H, s, CH2 pyrazol); 
7.09–8.27 (4H, m, H Ar); 7.52–7.94 (5H, m, H Ar); 8.00 (1H, s, NH, D2O 
exchangeable). 13C NMR spectrum, δ, ppm: 165.0 (C=O), 158.0 (C=O), 157.6, 155.6, 
142.7, 134.0, 131.7, 131.0, 129.1, 128.8, 125.9, 123.5, 115.2, 35.1 (CH2). Mass 
spectrum, m/z (Irel, %): 304 [M+] (54.3), 227 (100). Found, %: C 67.09; H 3.94; N 
18.40. C17H12N4O2. Calculated, %: C 67.11; H 3.95; N 18.42.  
3-(3-Amino-5-oxo-4,5-dihydropyrazol-1-yl)quinoxalin-2(1H)-one (10). To 
anhydrous compound 2 (1.0 g, 5.7 mmol) dissolved in ethyl cyanoacetate (0.6 ml, 
5.7 mmol) ethanol (30 ml) was added in an open beaker and swirled thoroughly. The 
mixture was irradiated in a microwave oven at 15-s interval for 3 min to give a clear 
solution, which was left to stand at room temperature. The solid crude product obtained 
was recrystallized from ethanol to afford compound 10 (0.7 g, 50.0 %) as an orange 
solid; mp 335–338oC. IR spectrum, νmax, cm–1: 3470 (NH), 3448–3132 (NH), 1667 
(C=O), 1605 (C=C), 1580 (C=N). UV spectrum, λmax (log εmax): 216 (6.37), 304 (5.82), 
330 (5.68 s), 336 (5.32), 348 (5.39). 1H NMR spectrum, δ, ppm: 2.20 (2H, s, CH2 
pyrazol); 7.12–8.29 (4H, m, H Ar); 8.00 (1H, s, NH, D2O exchangeable); 8.51 (2H, s, 
NH2, D2O exchangeable). 13C NMR spectrum, δ, ppm: 165.1 (C=O), 160.1 (C=O), 
158.2, 157.8, 142.9, 132.1, 129.3, 125.9, 123.7, 115.0, 71.8. Mass spectrum, m/z (Irel, %): 
243 [M+] (75). Found, %: C 54.33; H 3.72; N 28.83. C11H9N5O2. Calculated, %: C 54.32; 
H 3.70; N 28.81.  
 
Antibacterial activity assays 
 
Most of the organisms used were standard bacteria of National Collection for 
Industrial Bacteria (NCIB), while few others were locally isolated organisms (LIO). The 
gram-positive bacteria were Bacillus cereus (NCIB 6349), Bacillus stearothermophilus 
(NCIB 8222), Bacillus subtilis (NCIB 3610), Bacillus anthracis (LIO), Bacillus 
polymyxa (LIO), Corynebacterium pyogenes (LIO), Streptococcus faecalis (NCIB775), 
Staphylococcus aureus (NCIB 8588), Clostridium sporogenes (LIO), while the gram-
negative ones were Escherichia coli (NCIB 86), Pseudomonas fluorescence (NCIB 
3756), Klebsiella pneumonia (NCIB 418), Shigella dysenteriae (LIO), and 
Pseudomonas aeruginosa (NCIB 950).  
All the synthesized compounds 1–10 and streptomycin were screened for 
antibacterial activity on 9 gram-positive and 5 gram-negative bacterial strains using agar 
well diffusion method [33].  
With the aid of a sterile 1-ml pipette about 0.2 ml of the broth culture of the test 
organism was added to 18-ml sterile molten diagnostic sensitivity test agar (Biotech, 
Ltd.), which was already cooled down to 45oC. This was well mixed and poured into 
previously sterilized Petri dishes, which were properly labelled according to the test 
organisms. The medium was then allowed to set. With the aid of a sterile cork borer the 
required numbers of holes were bored into the medium. The wells were made of about 5 
mm to the edge of the plate. The wells were then filled up aseptically with the solution 
of the compound in DMSO using Pasteur pipettes. Streptomycin was used as a standard 
antibacterial agent at a concentration of 1000 µg/ml. The plates were allowed to stand 
for about 1 h on the bench for proper diffusion of the antibacterial agents into the 
medium and then incubated uprightly at 37oC for 24 h. Care was taken not to stockpile 
the plates. Clear inhibition zones, mm, indicated the relative susceptibility of the 
bacteria to compounds 1–10 and streptomycin standard. 
The minimum inhibitory concentration (MIC) was detected using the method of 
Russell and Furr [34]. Based on the level of resistance of some organisms and large 
inhibition zones experienced in others, MIC was selectively done for 5 gram-positive 
and 5 gram-negative bacterial strains. Different concentrations (7.8 and 1000.0 µg/ml) of 
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the compounds and standards were prepared using a two-fold dilution, which was 
prepared in a sterile plate with a sterile pipette and then mixed with 18 ml of molten 
nutrient agar. This was then allowed to set. The surface of the nutrient agar plate was 
allowed to dry before streaking with overnight broth cultures of the bacterial strains. The 
plates were then labelled accordingly and incubated at 37oC for up to 72 h. They were 
subsequently examined for the growth presence or absence. The lowest concentration 
preventing the bacteria growth was taken as the MIC of the compounds. This procedure 
was likewise repeated for streptomycin. 
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